Netxblockbuster, I totally agree.
- Dr Lakhotia has seemed to have worked diligently and quietly in the background and has achieved numerous successful relationships and earned the respect of the NCI, Pfizer UCSF, Merk, Newsora and others.
- Academically he has a PhD in biochemical engineering so he can speak the same languge as scientists and partners and he is probably viewed as a peer.
- His academic business training is an MBA, once again providing credentials to potential partners.
- He has biotech management experience beyond RVX/ZCC.
- From an RVX/ZCC point of view he is the devil they know. This is very diiferent than bringing in a biotech business guru from the outside and who is unknown to the (as Don pointed out) the RVX management team that has been at this for years. He is part of the cullture.
The downside of Dr Lakhotia is that he may be shaped too much by the (unsuccessful) busines culture at RVX.
It would seem to be a viable passing of the torch option and probably bring much needed energy and enthusiasm to the ZCC team as CEO.
Just some thoughts.
Toinv
